Get the Stockscreener App
1.29
8.49%
0.101
Akari Therapeutics Plc Adr stock is traded at $1.29, with a volume of 11,154.
It is up +8.49% in the last 24 hours and up +32.99% over the past month.
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
See More
Previous Close:
$1.189
Open:
$1.16
24h Volume:
11,154
Relative Volume:
0.21
Market Cap:
$34.15M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.7058
EPS:
-0.3481
Net Cash Flow:
-
1W Performance:
+12.17%
1M Performance:
+32.99%
6M Performance:
-63.46%
1Y Performance:
-50.38%
1-Day Range:
$1.16
$1.31
1-Week Range:
$1.15
$1.31
52-Week Range:
$0.90
$4.40
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Name
Akari Therapeutics Plc Adr
Sector
Industry
Phone
(646) 350-0702
Address
22 BOSTON WHARF ROAD, BOSTON
Compare AKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
1.29 | 34.15M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Sep-22-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-31-17 | Upgrade | Chardan Capital Markets | Sell → Neutral |
| Apr-17-17 | Reiterated | Chardan Capital Markets | Sell |
| Jul-11-16 | Initiated | Chardan Capital Markets | Sell |
View All
Akari Therapeutics Plc Adr Stock (AKTX) Latest News
Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Growth in Short Interest - Defense World
Akari Therapeutics appoints new CEO and board member - Investing.com
Akari Therapeutics names Samir Patel as CEO and adds board member - Investing.com India
Akari Therapeutics Names Interim CEO Patel as Permanent Chief, Adds Jazz Pharma Veteran to Board - StockTitan
Akari Therapeutics appoints new CFO - Investing.com
Akari Therapeutics appoints new CFO By Investing.com - Investing.com South Africa
AKTXAkari Therapeutics plc ADR (0.01 USD) Latest Stock News & Market Updates - StockTitan
Akari Therapeutics Strengthens Leadership: Former CFO Returns After $50M Fundraising Success - StockTitan
Akari Therapeutics Regains Nasdaq Compliance, Secures Market Listing Status | AKTX Stock News - StockTitan
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Benzinga
Akari Therapeutics Completes Peak Bio Merger, Secures $53.2M in Financing Commitments | AKTX Stock News - StockTitan
Akari Therapeutics shareholders approve Peak Bio merger - Investing.com
Akari Therapeutics shareholders approve Peak Bio merger By Investing.com - Investing.com UK
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger - StockTitan
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger - StockTitan
Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India
Akari Therapeutics PlcADR (AKTX) Price Target Increased by 45.45% to 81.60 - MSN
Akari Therapeutics appoints Rob Bazemore to board - Investing.com
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics - StockTitan
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy - StockTitan
Akari Therapeutics shareholders approve board and auditors - Investing.com India
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders - StockTitan
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights - StockTitan
Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering - StockTitan
Peak Bio (PKBO) Stock Price, News & Analysis - MarketBeat
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.25% - Investing.com Australia
GCI: Best & Worst Performing Small Cap Stocks for July 19, 2019 - StockNews.com
CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1% - Investing.com
Dow Jones News: Dow Rallies 200 Points After Macron and Le Pen Win First Round of French Election - Money Morning
Angion Biomedica (ANGN) Stock Price, News & Analysis - MarketBeat
Akari Therapeutics Plc Adr Stock (AKTX) Financials Data
There is no financial data for Akari Therapeutics Plc Adr (AKTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):